^
Association details:
| Biomarker: | MYC overexpression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | ICX-101 (MYC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4929 / 7 - ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression
Published date:
03/15/2023
Excerpt:
PDCs derived from SCLC showed higher MYC expression levels than NSCLC (P = 0.004). MYC was a prognostic factor, as the patient groups with the top and bottom 25 percentiles of MYC mRNA expression had an overall survival of 932.5 and 256 days, respectively (P = 0.029). However, MYC expression was predictive for the response to ICX-101, as the PDCs with the top 25 percentiles of MYC levels showed markedly lower AUC values than those with the bottom 25 percentile (P < 0.001).... ICX-101 is a potent MYC inhibitor that shows antitumor activity in lung cancer PDCs.
